Tildrakizumab for the prophylaxis of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. - Runaas L; Fank S; Palen K; Szabo A; Rein LE; Ying G; Salzman N; Samanas L; Abedin S; Chhabra S; Hamadani M; Longo W; et al. (Blood advances, 2026)